N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing work programmes. Optimisation..
N4 Pharma plc (LON:N4P) Chief Executive Officer Nigel Theobald caught up with DirectorsTalk for an exclusive interview to discuss H1 highlights, their new refined strategy, how the COVID pandemic created..
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss the latest interim results. Nigel talks us through the highlights of the first half, expands on a new refined..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended..
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its Covid-19 proof of concept work utilising Nuvec® loaded with Coronavirus plasmid. Nigel provides us with a snapshot of..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, has provided an update on its Covid-19 proof of concept work utilising..
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit of..
